Nortech Systems Inc: Form 10-Q for the period ended Sep 30, 2016
Filed with the SEC on Nov 2, 2016 and accepted by EDGAR at Nov 2, 2016, 16:32 ET.
Management's discussion and analysis
As filed, 26,972 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Overview
We are a Maple Grove, Minnesota based full-service electronics manufacturing services (“EMS”) contract manufacturer of wire and cable assemblies, printed circuit board assemblies, higher-level assemblies and box builds for a wide range of industries. We provide value added engineering services and technical support including design, testing, prototyping and supply chain management to customers mainly in the aerospace and defense, medical, and industrial equipment markets. We maintain facilities in Bemidji, Blue Earth, Eden Prairie, Mankato, Merrifield, and Milaca, Minnesota; Augusta, Wisconsin; Monterrey, Mexico; and Suzhou, China. All of our facilities are certified to one or more of the ISO/AS standards, including 9001, AS9100 and 13485, with most having additional certifications based on the needs of the customers they serve.
2016 Third Quarter Highlights
The third quarter of 2016 saw operating profit improvement on revenue of $29.7 million resulting in a gross margin of 12.7%, which is 320 basis points higher than the prior year’s third quarter. The gross margin was favorably impacted by our medical products and engineering service mix, lower material costs and selective pricing actions.
Operating profit for the third quarter of 2016 was $190,000, as compared to an operating loss of $66,000 for the prior year’s third quarter, an increase of $256,000. For the first nine months of the year ended 2016, income from operations was $301,000, as compared to a loss from operations of $751,000 for the same period last year, an improvement of $1.1 million. Negatively impacting the operating income for the three and nine months ended September 30, 2016, was an increase in our provision for doubtful accounts by $456,000 from a customer bankrupcy at the end of the third quarter.
Revenue for the nine month period ended September 30, 2016, of $87.6 million, increased by 4.6% over the prior year’s comparable period, led by our medical customers in both manufacturing and engineering services. Our investment in engineering services aided our medical market growth. Our defense revenue continues to adjust to the lower industry demand, while our industrial customers are down due to industry and economic factors in the oil, gas, energy and transportation market sectors.
The results for the three and nine month periods ended September 30, 2016, show progress in our transformation. The strategic investments in the past two years have positioned us to better capitalize on growth opportunities in the medical markets and improve our competitiveness by expanding our global footprint. For industrial and defense markets, we are focused on improving our asset utilization and profitability while supporting early engagement, design for manufacturability and rapid prototyping to promote profitable sales growth in the future for these two markets.
Summary of Results
Revenue was $29.7 million in the third quarter of 2016, as compared to $30.4 million in the third quarter of the prior year, a decrease of $0.7 million or 2%. Revenue results were mixed by markets, the medical market increased by $2.9 million or 27%, in the third quarter of 2016 as compared to the same period last year, but was offset by a decrease of 25% in the industrial market. Revenue from the aerospace and defense markets increased by 6% in the third quarter of 2016 as compared to the third quarter of 2015. The defense market sales growth in the quarter was mainly due to catching up on past due backlog.
Third quarter revenue for the medical market increased due to demand for both manufacturing and engineering services. Devicix engineering services revenue before eliminations in the quarter was $1.8 million which accounted for $0.8 million or 27% of the $2.9 million increase as compared to the third quarter of 2015.
The net decrease in the industrial market sector of $3.8 million in the third quarter of 2016 as compared to the same quarter of 2015, resulted primarily from lower demand levels from our semiconductor, agriculture and transportation equipment customers.
Our third quarter gross profit increased to 12.7% of sales versus 9.5% in the third quarter of the prior year. Our gross profit percentage for the nine months ended September 30, 2016 was 11.7% compared to 9.8% for the nine months ended September 30, 2015. Gross profit improvements in both the third quarter and the first nine months of the year were driven by the sales growth and mix in medical products and engineering services, selective price actions, and lower material costs. Cost of goods sold for the three and nine months ended September 30, 2016, includes $216,000 and $579,000 of startup costs for our new Asia manufacturing facility, respectively.
Selling, general and administrative expenses for the three months ended September 30, 2016 and 2015 was $3.6 million or 12.1% of sales and $3.0 million or 9.7% of sales, respectively, an increase of $640,000. Selling, general and administrative expenses for the nine months ended September 30, 2016 and 2015 was $10.0 million or 11.4% of sales and $8.9 million or 10.7% of sales, respectively, an increase of $1.1 million. The increase in selling, general and administrative expense was due in part to an increase in our provision for doubtful accounts by $456,000 due to a customer bankruptcy, as well as increased operating expenses for Devicix engineering services and new China facility.
Third quarter 2016 income from operations was $190,000 as compared to an operating loss of $66,000 for the third quarter in 2015. For the first nine months of 2016, income from operations was $301,000 as compared to a loss from operations of $751,000 for the same period last year. The improvement of $256,000 for the quarter and $1.1 million for the nine months was due to the gross margin improvement in the mix of medical products and services, pricing adjustments and cost reductions.
Net income for the three months ended September 30, 2016 was $63,000 or $0.02 per basic and diluted common share, compared to net loss for the three months ended September 30, 2015 of $124,000 or $0.05 per basic and diluted common share. Net loss for the first nine months of 2016 was $54,000 or $0.02 per basic and diluted common share, compared to net loss of $695,000 or $0.25 per basic and diluted common share for the same period in 2015.
Cash provided by operating activities for the first nine months of 2016 was $1.9 million, as compared to cash provided by operating activities in the first nine months of 2015 of $3.9 million. The noncash addback of depreciation and amortization along with increased receivable collections and increases in accounts payable, through the extension of terms and conditions, has positively impacted cash flows and offset the increase in inventory.
Results of Operations
The following table presents statements of operations data as percentages of total net sales for the periods indicated:
| Three Months Ended September 30 2016 | 2015 | Nine Months Ended September 30 2016 | 2015 | |
|---|---|---|---|---|
| Net Sales | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of Goods Sold | 87.3 | 90.5 | 88.3 | 90.2 |
| Gross Profit | 12.7 | 9.5 | 11.7 | 9.8 |
| Selling Expenses | 3.8 | 4.1 | 4.3 | 4.7 |
| General and Administrative Expenses | 8.3 | 5.6 | 7.1 | 6.0 |
| Income (Loss) from Operations | 0.6 | (0.2) | 0.3 | (0.9) |
| Other Expenses, Net | (0.4) | (0.4) | (0.4) | (0.4) |
| Income (Loss) Before Income Taxes | 0.2 | (0.6) | (0.1) | (1.3) |
| Income Tax Benefit | 0.0 | (0.2) | 0.0 | (0.5) |
| Net Income (Loss) | 0.2% | (0.4)% | (0.1)% | (0.8)% |
Net Sales
We reported net sales of $29.7 million for the three months ended September 30, 2016 and $30.4 million for the three months ended September 30, 2015. We reported net sales of $87.6 for the nine months ended September 30, 2016 and $83.8 million for the prior year’s comparable period.
For the third quarter of 2016, our medical and defense customers led the increase in revenue, up 27% and 6%, respectively, over the prior year’s third quarter, and 34% and 16%, respectively, for the nine months ended September 30, 2016, as compared to the nine months ended September 30, 2015. Devicix engineering services revenue before eliminations for the third quarter of 2016 was $1.8 million, which accounted for a $0.8 million increase in medical revenue before eliminations as compared to the third quarter of 2015. For the nine months ended September 30, 2016, Devicix engineering services revenue before eliminations was $5.4 million, which accounted for a $4.4 million increase in medical revenue before eliminations as compared to the same period in 2015, which was due to the acquisition of Devicix taking place on July 1, 2015. These increases were offset by a decrease in revenue from our industrial customers of 25% for the third quarter of 2016, as compared to the third quarter of 2015, and 17% for the nine months ended September 30, 2016, as compared to the nine months ended September 30, 2015. Our industrial customers in the agriculture, energy, transportation and semi-conductor market sectors are being impacted by a sluggish overall economy so far during 2016.
Net sales by our major EMS industry markets for the three and nine month periods ended September 30, 2016 and 2015 were as follows:
| Three Months Ended September 30 | Nine Months Ended September 30 | |
|---|---|---|
| 2016 2015% | 2016 2015% | |
| (in thousands) | $$ Change | $$ Change |
| Aerospace and Defense | 4,240 4,004 6 | 12,427 10,724 16 |
| Medical | 13,776 10,887 27 | 38,058 28,376 34 |
| Industrial | 11,702 15,518 (25) | 37,129 44,650 (17) |
| Total Sales | 29,718 30,409 (2) | 87,614 83,750 5 |
17
Backlog
Our 90-day order backlog as of September 30, 2016 was $23.9 million, a 5% increase from the beginning of the quarter and flat as compared to the prior year. Backlog for our medical customers has increased 35% over the prior year and 7% over the prior quarter. The aerospace and defense backlog decreased 26% from the beginning of the quarter as past due orders were reduced significantly and our industrial customers’ backlog increased 24% from the beginning of the quarter improving our position heading into the fourth quarter for those customer trying to finish out the year strong. Our backlog consists of firm purchase orders and we expect a major portion of the current 90 day backlog to be realized as revenue during the following quarter.
90 day backlog by our major EMS industry markets are as follows:
(in thousands)
| Backlog as of the Quarter Ended September 30 2016 | June 30 2016 | September 30 2015 | |
|---|---|---|---|
| Aerospace and Defense | $3,565 | $4,791 | $5,455 |
| Medical | 12,282 | 11,428 | 9,120 |
| Industrial | 8,074 | 6,526 | 9,396 |
| Total Backlog | $23,921 | $22,745 | $23,971 |
Our 90 day backlog varies due to order size, manufacturing delays, contract terms and conditions and timing from customer delivery schedules and releases. These variables cause inconsistencies in comparing the backlog from one period to the next.
Gross Profit
Gross profit as a percent of net sales for the three months ended September 30, 2016 and 2015, was 12.7% and 9.5%, respectively. Gross profit as a percentage of net sales for the nine months ended September 30, 2016 and 2015, was 11.7% and 9.8%, respectively. The increase in gross profit in the third quarter and the first nine months of 2016 was due to medical mix and volume, increased engineering service revenue, selective pricing actions and material cost reductions.
Selling Expense
Selling expense for the three months ended September 30, 2016 and 2015 was $1.1 million or 3.8% of sales and $1.2 million or 4.1% of sales, respectively. Selling expense for the nine months ended September 30, 2016 and 2015 was $3.7 million or 4.3% of sales and $3.9 million or 4.7% of sales, respectively. The decrease is due to the timing of expenses. We expect to continue at an increased rate of funding for business development activities and marketing initiatives to maintain existing business and stimulate sales growth.
General and Administrative Expense
General and administrative expenses for the three months ended September 30, 2016 and 2015, were $2.5 million or 8.3% of sales and $1.7 million or 5.3% of sales, respectively. General and administrative expenses for the nine months ended September 30, 2016 and 2015, were $6.3 million or 7.1% of sales and $5.0 million or 5.9% of sales, respectively. The increase in general and administrative expense for the periods listed was due an increase in our provision for doubtful accounts by $456,000 due to a customer bankruptcy, along with additional costs related to operating expenses for Devicix engineering services and new China facility.
Income Taxes
On a quarterly basis, we estimate what our effective tax rate will be for the full fiscal year and record a quarterly income tax provision based on the anticipated rate. As the year progresses, we refine our estimate based on the facts and circumstances, including discrete events, by each tax jurisdiction. Our effective tax rate for the three and nine months ended September 30, 2016 was (26%) and 51%, respectively. Our effective tax rate for the three and nine months ended September 30, 2015 was 38% and 36%, respectively. The effective tax rate for the year ended December 31, 2016 is expected to be 32% compared to 36% for the year ended December 31, 2015. The decrease is due mainly to the impact of the federal research and development credit.
The differences between federal income taxes computed at the federal statutory rate and reported income taxes for the three and nine months ended September 30, 2016 and 2015 are as follows:
| Three Months Ended September 30 2016 | 2015 | Six Months Ended September 30 2016 | 2015 | |
|---|---|---|---|---|
| Statutory federal tax benefit | $17,000 | $(57,000) | $(38,000) | $(327,000) |
| State income taxes (benefits) | 8,000 | (6,000) | 24,000 | (32,000) |
| Income tax credits | (20,000) | (14,000) | (60,000) | (39,000) |
| Return to provision true up | (22,000) | 5,000 | (22,000) | 5,000 |
| Foreign tax benefit | 44,000 | — | 44,000 | — |
| Other | (40,000) | (4,000) | (4,000) | (4,000) |
| Income tax benefit | $(13,000) | $(76,000) | $(56,000) | $(397,000) |
Liquidity and Capital Resources
We have satisfied our liquidity needs over the past several years with cash flows generated from operations and an operating line of credit through WFB. We also have real estate and equipment term loans. We have a credit agreement with WFB which was most recently amended on September 29, 2016 and provides for a line of credit arrangement of $15.0 million that expires, if not renewed, on May 31, 2018. The credit arrangement also has a $1.8 million real estate term note outstanding with a maturity date of March 31, 2027, an additional $1.7 million real estate term note outstanding that is due, if not renewed, on December 31, 2027, an equipment loan for $2.7 million and a term loan facility of up to $1.0 million for capital expenditures, both with maturity dates of May 31, 2018.
Both the line of credit and real estate term notes are subject to fluctuations in the LIBOR rates. The line of credit, real estate term notes, and equipment loans with WFB contain certain covenants which, among other things, require us to adhere to regular reporting requirements, abide by annual shareholder dividend limitations, maintain certain financial performance, and limit the amount of annual capital expenditures. The availability under our line is subject to borrowing base requirements, and advances are at the discretion of the lender. The line of credit is secured by substantially all of our assets.
On September 30, 2016, we had outstanding advances of $8.2 million under the line of credit and unused availability of $6.1 million supported by our borrowing base. We believe our financing arrangements and cash flows to be provided by operations will be sufficient to satisfy our future working capital needs. Our working capital was $20.4 and $20.7 million as of September 30, 2016 and December 31, 2015, respectively.
Our credit agreement with WFB requires us to maintain a minimum fixed charge coverage ratio of not less than 1.15 to 1.00. The fixed charge coverage ratio at September 30, 2016 was 1.38 to 1.00.
Net cash provided by operating activities for the nine months ended September 30, 2016 was $1.9 million. The noncash addback of depreciation and amortization positively impacted cash flows along with decreases in accounts receivable and increases in accounts payable, through the extension of terms and conditions, offset by increases in inventory.
Net cash used in investing activities of $1.7 million for the nine months ended September 30, 2016 is comprised of property and equipment purchases to support the business, including $356,000 in purchases related to our investment in China.
Cash conversion cycle:
| Nine Months Ended September 30, 2016 | September 30, 2015 | |
|---|---|---|
| Days in trade accounts receivable | 55 | 63 |
| Days in inventory | 77 | 73 |
| Days in accounts payable | (53) | (52) |
| Cash conversion cycle | 79 | 84 |
We calculate days in accounts receivable as accounts receivable for the respective quarter divided by annualized sales for the respective quarter by day. We calculate days in inventory and accounts payable as each balance sheet line item for the respective quarter divided by annualized cost of sales for the respective quarter by day. We calculate cash conversion cycle as the sum of days in receivable and inventory less days in accounts payable. Items which may cause the cash conversion cycle in a particular period to differ include, but are not limited to, changes in business mix, changes in payment terms and the timing of revenue recoginition and inventory purchases within the period. Days in accounts receivable for the nine months ended September 30, 2016, improved eight days compared to the nine months ended September 30, 2015, as a result of timing of collections. The improvements were partially offset by an increase in Days in Inventory which was caused by increased inventory on hand related to delays in shipments, delays in new product launches, product transfer safety stock and projects on hold for customer design issues.
Off-Balance Sheet Arrangements
We have not engaged in any off-balance sheet activities as defined in Item 303(a)(4) of Regulation S-K.
Critical Accounting Policies and Estimates
Our significant accounting policies and estimates are summarized in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2015. There have been no significant changes in these critical accounting policies since December 31, 2015. Some of our accounting policies require us to exercise significant judgment in selecting the appropriate assumptions for calculating financial estimates. Such judgments are subject to an inherent degree of uncertainty. These judgments are based on our historical experience, known trends in our industry, terms of existing contracts and other information from outside sources, as appropriate. Actual results could differ from these estimates.
Recent Accounting Pronouncements
In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting, which changes how companies account for certain aspects of share-based payments to employees. The new guidance requires all income tax effects of awards to be recognized in the income statement when the awards vest or are settled, allows an employer to repurchase more of an employee’s shares than previously allowed for tax withholding purposes without triggering liability accounting, allows a company to make a policy election to account for forfeitures as they occur, and eliminates the requirement that excess tax benefits be realized before companies can recognize them. The new guidance also requires excess tax benefits and tax shortfalls to be presented on the cash flow statement as an operating activity rather than as a financing activity, and clarifies that cash paid to a tax authority when shares are withheld to satisfy its statutory income tax withholding obligation are to be presented as a financing activity. The standard is effective for our financial statements issued for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating the impact of adoption of this ASU on our consolidated financial statements.
During February 2016, the FASB issued ASU 2016-02, “Leases.” ASU 2016-02 was issued to increase transparency and comparability among organizations by recognizing all lease transactions (with terms in excess of 12 months) on the balance sheet as a lease liability and a right-of-use asset (as defined). ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with earlier application permitted. Upon adoption, the lessee will apply the new standard retrospectively to all periods presented or retrospectively using a cumulative effect adjustment in the year of adoption. We are currently assessing the effect that ASU 2016-02 will have on its results of operations, financial position and cash flows.
In November 2015, the FASB issued ASU 2015-17, “Income Taxes (Topic 740) Balance Sheet Classification of Deferred Taxes” which requires that deferred tax assets and liabilities be classified as noncurrent in a classified balance sheet. The amendment takes effect for public entities for fiscal years beginning after December 15, 2016, with early adoption available. We have adopted the standard in this report and reclassified comparative periods for consistency.
In July 2015, the FASB issued ASU 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory.” This standard changes the measurement principle for certain inventory methods from the lower of cost or market to the lower of cost and net realizable value. Net realizable value is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This standard does not apply to inventory that is measured using Last-in First-out (“LIFO”) or the retail inventory method. The provisions of ASU 2015-11 are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. The Company does not expect this guidance to have a significant impact on its consolidated financial statements.
In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)”. This standard outlines a single comprehensive model for companies to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that revenue is recognized when a customer obtains control of a good or service. A customer obtains control when it has the ability to direct the use of and obtain the benefits from the good or service. Transfer of control is not the same as transfer of risks and rewards, as it is considered in current guidance. We will also need to apply new guidance to determine whether revenue should be recognized over time or at a point in time. This standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2017, with no early adoption permitted, using either of two methods: (a) retrospective to each prior reporting period presented with the option to elect certain practical expedients as defined within ASU 2014-09; or (b) retrospective with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application and providing certain additional disclosures as defined in ASU 2014-09. We have not yet selected a transition method and are currently evaluating the impact of the pending adoption of ASU 2014-09 on the consolidated financial statements.
Forward-Looking Statements
Those statements in the foregoing report that are not historical facts are forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements generally will be accompanied by words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “possible,” “potential,” “predict,” “project,” or other similar words that convey the uncertainty of future events or outcomes. Although we believe these forward-looking statements are reasonable, they are based upon a number of assumptions concerning future conditions, any or all of which may ultimately prove to be inaccurate. Forward-looking statements involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from the forward-looking statements include, without limitation:
- Volatility in the marketplace which may affect market supply and demand for our products;
- Increased competition;
- Changes in the reliability and efficiency of operating facilities or those of third parties;
- Risks related to availability of labor;
- Increase in certain raw material costs such as copper;
- Commodity and energy cost instability;
- Dependence on certain customers;
- Possible customer cancellations of orders, impact of financial difficulty of customers and other factors that could cause losses relating to customer orders;
- General economic, financial and business conditions that could affect our financial condition and results of operations; and
- Availability of raw material components.
The factors identified above are believed to be important factors (but not necessarily all of the important factors) that could cause actual results to differ materially from those expressed in any forward-looking statement made by us. Unpredictable or unknown factors not discussed herein could also have material adverse effects on forward-looking statements. All forward-looking statements included in this Form 10-Q are expressly qualified in their entirety by the forgoing cautionary statements. We undertake no obligations to update publicly any forward-looking statement (or its associated cautionary language) whether as a result of new information or future events.
Please refer to forward-looking statements and risks as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015.
Controls and procedures
As filed, 1,458 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
In accordance with Rule 13a-15(b) of the Securities Exchange Act of 1934 (the “Exchange Act”), as of the end of the period covered by this Quarterly Report on Form 10-Q, our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act). These controls and procedures are designed to ensure that information required to be disclosed in the Company’s Exchange Act reports is (1) recorded, processed, summarized and reported in a timely manner, and (2) accumulated and communicated to management, including the Company’s Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon their evaluation of these disclosure controls and procedures as of the date of the evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the disclosure controls and procedures were effective.
Changes in Internal Control Over Financial Reporting
There was no change in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2016-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2016-07-01 to 2016-09-30 | $29.7m | us-gaap:SalesRevenueNet |
| Revenue | 9 months2016-01-01 to 2016-09-30 | $87.6m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months2016-07-01 to 2016-09-30 | $25.9m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2016-01-01 to 2016-09-30 | $77.3m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2016-07-01 to 2016-09-30 | $3.8m | us-gaap:GrossProfit |
| Gross profit | 9 months2016-01-01 to 2016-09-30 | $10.3m | us-gaap:GrossProfit |
| Operating income | 3 months2016-07-01 to 2016-09-30 | $189.8k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2016-01-01 to 2016-09-30 | $300.8k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2016-07-01 to 2016-09-30 | $139.5k | us-gaap:InterestExpense |
| Interest expense | 9 months2016-01-01 to 2016-09-30 | $410.7k | us-gaap:InterestExpense |
| Income tax | 3 months2016-07-01 to 2016-09-30 | −$13.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2016-01-01 to 2016-09-30 | −$56.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2016-07-01 to 2016-09-30 | $63.3k | us-gaap:NetIncomeLoss |
| Net income | 9 months2016-01-01 to 2016-09-30 | −$54.0k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2016-07-01 to 2016-09-30 | $0.02 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2016-01-01 to 2016-09-30 | −$0.02 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2016-07-01 to 2016-09-30 | $0.02 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2016-01-01 to 2016-09-30 | −$0.02 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2016-07-01 to 2016-09-30 | 2,749,944 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2016-01-01 to 2016-09-30 | 2,747,288 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Capital expenditure | 9 months2016-01-01 to 2016-09-30 | $1.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2016-09-30 | $61.1k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2016-09-30 | $41.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2016-09-30 | $57.2m | us-gaap:Assets |
| Current liabilities | At period end2016-09-30 | $20.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2016-09-30 | $35.0m | us-gaap:Liabilities |
| Long-term debt | At period end2016-09-30 | $5.2m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2016-09-30 | $1.6m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2016-09-30 | $22.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001104659-16-154191. Last ingested by Listed: Nov 12, 2026, 19:20 ET. Listed shows no prices and gives no investment advice.